• eTheRNA
  • Follow our progress in developing products that have the potential to transform the future of cancer treatment

eTheRNA immunotherapies opens new research base in Ghent

Niel (Belgium), 8 May 2019 - eTheRNA immunotherapies, a clinical-stage company developing cancer immunotherapies from its proprietary mRNA TriMix platform, is expanding its operation into new research laboratories this spring at the Bioscape campus in Ghent, Belgium. This new research base comes in addition to the existing manufacturing and clinical development base in Niel. The new laboratories will accommodate the company’s enlarged research and preclinical teams.